Search research articles
Contact Us
Filters
Showing results (581-590 of 724) with videos related to
Page
of 73
Sort By:
The Journal of Cell Biology
|
March 27, 2001
Intraarterial injection of muscle-derived CD34(+)Sca-1(+) stem cells restores dystrophin in mdx mice
Y Torrente, J P Tremblay, F Pisati, et al.
JAMA Dermatology
|
February 1, 2023
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials
Amy S Paller, Jonathan I Silverberg, Michael J Cork, et al.
Anais Da Academia Brasileira De Ciencias
|
July 8, 2026
Conservation, diversity, and evaluation of Cassava landraces for northern Mato Grosso
Auana Vicente Tiago, Fernando S Rossi, Eliane Cristina M DE Pedri, et al.
Cytometry
|
July 15, 1999
Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay
S D Demo, E Masuda, A B Rossi, et al.
Journal of the American Academy of Dermatology
|
January 24, 2025
Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)
Robert Bissonnette, Elena Goleva, Evgeny Berdyshev, et al.
Dermatology and Therapy
|
June 18, 2021
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
Christopher Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, et al.
Medical Physics
|
April 25, 2001
Intensity modulated proton therapy: a clinical example
A J Lomax, T Boehringer, A Coray, et al.
European Journal of Cancer Care
|
August 24, 2017
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study
F Dalenc, V Ribet, A B Rossi, et al.
The British Journal of Dermatology
|
August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology
|
June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis
A Wollenberg, L A Beck, A Blauvelt, et al.
Page
of 73
Search research articles
Search
Showing results (581-590 of 724) with videos related to
Sort By:
Page
of 73
The Journal of Cell Biology
|
March 27, 2001
Intraarterial injection of muscle-derived CD34(+)Sca-1(+) stem cells restores dystrophin in mdx mice
Y Torrente, J P Tremblay, F Pisati, et al.
JAMA Dermatology
|
February 1, 2023
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials
Amy S Paller, Jonathan I Silverberg, Michael J Cork, et al.
Anais Da Academia Brasileira De Ciencias
|
July 8, 2026
Conservation, diversity, and evaluation of Cassava landraces for northern Mato Grosso
Auana Vicente Tiago, Fernando S Rossi, Eliane Cristina M DE Pedri, et al.
Cytometry
|
July 15, 1999
Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay
S D Demo, E Masuda, A B Rossi, et al.
Journal of the American Academy of Dermatology
|
January 24, 2025
Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)
Robert Bissonnette, Elena Goleva, Evgeny Berdyshev, et al.
Dermatology and Therapy
|
June 18, 2021
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
Christopher Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, et al.
Medical Physics
|
April 25, 2001
Intensity modulated proton therapy: a clinical example
A J Lomax, T Boehringer, A Coray, et al.
European Journal of Cancer Care
|
August 24, 2017
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study
F Dalenc, V Ribet, A B Rossi, et al.
The British Journal of Dermatology
|
August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology
|
June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis
A Wollenberg, L A Beck, A Blauvelt, et al.
Page
of 73